Trending: Take cover: Amazon’s big umbrellas renew a stormy old debate about Seattle culture
Hans Bishop
Juno Therapeutics CEO Hans Bishop speaking at the 2016 GeekWire Summit. (GeekWire Photo / Dan DeLong)

Seattle-based biotech company Juno Therapeutics beat analyst expectations in its second quarter revenue Thursday, reporting $21.3 million in revenue for the quarter compared to an analyst estimate of $15.82 million.

But it narrowly missed expectations on per-share loss, posting a loss of $0.74 per share, slightly worse than the expected loss of $0.72. The mixed bag follows a turbulent period for the company after it pulled its most advanced drug candidate. Juno has since revved up R&D efforts to push several other drug candidates into clinical trials, increasing losses.

The company is developing CAR T immunotherapy treatments for cancer, cutting-edge medical science that uses genetically altered immune cells to kill cancer. Last month, biotech giant Novartis passed the first FDA hurdle to get its own CAR T immunotherapy approved on the market, which would be a first for the treatment.

Thursday, Juno highlighted positive results in early trials of its flagship drug, JCAR017, a treatment for those with advanced leukemia who haven’t responded to current treatment options. Half of the patients in a small clinical trial went into remission, no small task for such a sick patient group.

“It has been a historic last several months for the CAR T field, highlighting the potential of these therapies for patients. Juno is well-positioned to make a major impact, particularly with the potential best-in-class profile emerging for JCAR017,” Juno CEO Hans Bishop said in a press release. “We look forward to starting the pivotal cohort for JCAR017 this quarter as well as expanding the use of this drug into broader populations over the coming year.”

Like what you're reading? Subscribe to GeekWire's free newsletters to catch every headline


Job Listings on GeekWork

Find more jobs on GeekWork. Employers, post a job here.